This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Currently there are no upcoming events.
Educating and empowering the cancer community by connecting patients and caregivers with leading experts in immunotherapy
Educating and empowering the Hispanic and Latino cancer community by connecting patients and caregivers with leading experts in immunotherapy in the Spanish language.
We are thrilled to offer the first CRI Virtual Immunotherapy Patient Summit. Register for free today.
Free event for patients, caregivers, and advocates to learn about new breakthroughs in cancer immunotherapy from Drs. Elizabeth M. Jaffee, Marijo Bilusic, Ranee Mehra, and Suzanne L. Topalian.
Free event for patients, caregivers, and advocates to learn about new breakthroughs in cancer immunotherapy with Drs. Adi Diab, Jianjun Gao, Andrew Sikora, and Valentina Hoyos Velez.
Free event for patients, caregivers, and advocates to learn about new breakthroughs in cancer immunotherapy with Drs. Vamsidhar Velcheti, Sylvia Adams, Claire Friedman, and Gulam A. Manji.
Register for a free, virtual event for patients, caregivers, and advocates to learn about new breakthroughs in cancer immunotherapy.
Free event for patients, caregivers, and advocates to learn about new breakthroughs in cancer immunotherapy with Drs. David Reardon, Suzanne Baumeister, Justin Gainor, and Kimmie Ng.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
A recent diabetes-related discovery by CRI Lloyd J. Old STAR Dr. Andrea Schietinger has promising implications for cancer immunotherapy
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.